Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Osimertinib Frontline Standard of Care for EGFR+ NSCLC

July 27th 2019, 4:59am

International Lung Cancer Congress

The frontline standard of care for patients with EGFR-mutant non–small cell lung cancer remains an EGFR TKI, most commonly osimertinib in the United States.

Immunotherapy Continues to Evolve Multimodal Stage III NSCLC Treatment

July 27th 2019, 4:38am

International Lung Cancer Congress

Checkpoint inhibitors in the neoadjuvant setting, as consolidation post-chemoradiation, or in combination with concurrent chemoradiation, are all strategies actively being pursued in the locally advanced non–small cell lung cancer setting.

"Hitting the Target" Should Be Focus of Next-Generation Agents in Lung Cancer

July 26th 2019, 11:54pm

International Lung Cancer Congress

The future generation of agents in lung cancer should be evaluated in improved predictive biomarker-driven trials to identify patients who are most likely to benefit or have detriment for both TKIs and checkpoint inhibitors.

Dr. Herbst on Immuno-Oncology Combinations in Lung Cancer

July 26th 2019, 5:46am

International Lung Cancer Congress

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses combinations with immunotherapy in lung cancer.

Dr. Reckamp on Pivotal Data in METex14-Altered NSCLC

July 26th 2019, 5:37am

International Lung Cancer Congress

Karen L. Reckamp, MD, MS, discusses pivotal findings with the highly selective MET inhibitors, tepotinib and capmatinib in patients with MET exon 14-altered advanced non–small cell lung cancer.

Future Lung Cancer Research Requires Precision Medicine Ecosystem

July 26th 2019, 4:20am

International Lung Cancer Congress

There is a growing need to share information across research settings and the community, with the rapid introduction of new biomarkers, cancer detection strategies, immunotherapies, and targeted therapies. This synchronization of system biology tool datasets could help create a new digital ecosystem focused on precision medicine.

Window-of-Opportunity Strategies Continue to Make Headway in Lung Cancer

July 26th 2019, 4:13am

International Lung Cancer Congress

Paul A. Bunn Jr, MD, highlights the benefits of preoperative window-of-opportunity studies, specifically with immunotherapy in lung cancer.

Novel Research Methods Could Expedite New Drug Development

July 26th 2019, 2:09am

International Lung Cancer Congress

Optimizing the methods for preclinical research with an emphasis on patient-derived models, may help speed up the translation of new treatment advances from the laboratory to the clinic.

Concurrent Ibrutinib With CAR T-Cell Therapy Improves ORR, Reduces Severe CRS in High-Risk CLL

June 22nd 2019, 2:02am

International Conference on Malignant Lymphoma

Patients with high-risk relapsed/refractory chronic lymphocytic leukemia who failed or were intolerant of ibrutinib derived more benefit from CD19‐targeted CAR T-cell therapy when the BTK inhibitor was concurrently administered than when it was not.

Dr. Siddiqi on CAR T-Cell Therapy in Relapsed/Refractory CLL/SLL

June 21st 2019, 11:53pm

International Conference on Malignant Lymphoma

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the phase I/II TRANSCEND CLL 004 trial, which evaluated the efficacy of anti-CD19 CAR T cells in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Nivolumab/Brentuximab Vedotin Combo Is Highly Active in Relapsed/Refractory PMBCL

June 21st 2019, 11:21pm

International Conference on Malignant Lymphoma

Nearly three-fourths of patients with relapsed/refractory primary mediastinal large B-cell lymphoma responded to a combination of nivolumab (Opdivo) plus brentuximab vedotin (Adcetris).

Lisocabtagene Maraleucel Continues to Show Promise in Relapsed/Refractory CLL

June 21st 2019, 10:41pm

International Conference on Malignant Lymphoma

The CAR T-cell therapy lisocabtagene maraleucel demonstrated high rates of response, including minimum residual disease in blood and marrow in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Rapid Changes in Multiple Myeloma Provide a Windfall of Treatment Options

June 21st 2019, 8:50pm

International Conference on Malignant Lymphoma

S. Vincent Rajkumar, MD, discusses the rapidly changing landscape for the treatment of multiple myeloma, the future of immunomodulatory drugs, and whether quadruplet regimens will become more frequent.

Dr. Song on Zanubrutinib Activity in Relapsed/Refractory MCL

June 21st 2019, 6:05pm

International Conference on Malignant Lymphoma

Yuqin Song, MD, PhD, chief physician and deputy director of the Lymphoma Department at Peking University Cancer Hospital, Beijing, China, discusses the updated data from the phase II trial evaluating the efficacy of zanubrutinib (BGB-3111-206) in patients with relapsed/refractory mantle cell lymphoma.

Acalabrutinib Is Viable Option for Ibrutinib-Intolerant Relapsed/Refractory CLL

June 21st 2019, 12:31am

International Conference on Malignant Lymphoma

Acalabrutinib elicited high rates of response as well as prolonged survival and was well tolerated in patients with chronic lymphocytic leukemia who demonstrated intolerance to ibrutinib.

Genetic Analysis Provides Insight Into Venetoclax/Obinutuzumab Benefit in Frontline CLL

June 20th 2019, 11:46pm

International Conference on Malignant Lymphoma

In a careful evaluation of chemotherapy‐free regimens, the combination of obinutuzumab plus venetoclax compared to obinutuzumab plus chlorambucil, objective and complete response rates, as well as progression-free survival were superior with the venetoclax combination in the overall study population and across all genetic subgroups evaluated in patients with chronic lymphocytic lymphoma.

Efficacy Data Support Acalabrutinib Across CLL Settings

June 20th 2019, 11:20pm

International Conference on Malignant Lymphoma

The phase III ASCEND trial is only one of the pivotal trials that have presented data to suggest that acalabrutinib (Calquence) could see an FDA approval for the frontline treatment of patients with chronic lymphocytic leukemia.

Dr. Lugtenburg on Maintenance Rituximab in DLBCL

June 20th 2019, 7:56pm

International Conference on Malignant Lymphoma

Pieternella J. Lugtenburg, MD, PhD, an internist and hematologist at Erasmus Medical Center in Rottenham, Netherlands, discusses the use of rituximab as maintenance therapy in patients with diffuse large B-cell lymphoma.

Dr. Rajkumar on Quadruplet Regimens in Multiple Myeloma Treatment

June 20th 2019, 7:38pm

International Conference on Malignant Lymphoma

S. Vincent Rajkumar, a professor of Medicine at the Mayo Clinic, Rochester, Minnesota, discusses the prevalence of quadruplet regimens in treating patients with multiple myeloma.

Brown Highlights the Future of Acalabrutinib in CLL Treatment

June 20th 2019, 1:31am

International Conference on Malignant Lymphoma

Jennifer R. Brown, MD, PhD, highlights the new and upcoming research regarding acalabrutinib in the field of chronic lymphocytic leukemia.